Herantis Pharma Oyj
HRPMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,600 | $2,700 | $5,000 | $6,200 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,488 | $2 | $2,649 | $2,850 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$61 | -$4,590 | $135 | $0 |
| Operating Expenses | $5,026 | -$154 | $7,993 | $9,050 |
| Operating Income | -$5,026 | $154 | -$7,993 | -$9,050 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $87 | $125 | -$1,331 | -$306 |
| Pre-Tax Income | -$4,939 | $280 | -$9,324 | -$12,767 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,939 | $280 | -$9,324 | -$23,576 |
| % Margin | – | – | – | – |
| EPS | -0.24 | 0.016 | -0.64 | -2.2 |
| % Growth | -1,572.4% | 102.5% | 70.9% | – |
| EPS Diluted | -0.24 | 0.016 | -0.64 | -2.2 |
| Weighted Avg Shares Out | 20,161 | 17,195 | 14,654 | 10,205 |
| Weighted Avg Shares Out Dil | 20,161 | 17,195 | 14,654 | 10,205 |
| Supplemental Information | – | – | – | – |
| Interest Income | $93 | $677 | $1 | $0 |
| Interest Expense | $6 | $552 | $1,332 | $63 |
| Depreciation & Amortization | $0 | -$0 | $15,971 | $15,971 |
| EBITDA | -$4,934 | $831 | $7,979 | $6,921 |
| % Margin | – | – | – | – |